BDD Press Releases

BDD’s Phase 1 Trial Reports Positive Phase I Results for Novel Cognitive Impairment Associated with Schizophrenia Treatment

BDD is delighted to have supported Monument Therapeutics in conducting…

In the News – BDD Taking Years Off Drug Development

      SCOTTISH COMPANY TAKING YEARS…

BDD’s OralogiK™ Technology Powers Advancement of A Once-Daily Anxiety Treatment

BDD Pharma Ltd. is pleased to announce the advancement of another…

BDD Pharma opens brand new GMP manufacturing facility following £2m in funding

  Media release 8 April 2025 BDD Pharma opens brand…

BDD’s OralogiK™ technology dosed in Parkinson’s patients for the first time. – Phase 1b trial of CP-012

BDD's OralogiK™ technology dosed in Parkinson's patients for…

BDD secures £2M to fuel expansion in early phase clinical trials following record year

BDD secures £2M to fuel expansion in early phase clinical trials…

BDD Pharma Ltd Unveils Updated Logo for 2023

Glasgow, Scotland, United Kingdom – BDD Pharma Ltd, a…

Claire Madden-Smith joins BDD Pharma Board as Non-Executive Director

BDD PHARMA LIMITED For immediate release – June 13th 2022 Claire…